MarginsXMarginsX
Home › Markets › Health Care › LEXX

Lexaria Bioscience Corp. (LEXX)

LEXX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.41
-0.68% on the day
Market cap
$9.3M
Nano cap
Revenue · 2025
$706K
+52.0% on 2024
Net income · 2025
-$11.9M
-1686.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-08-31, https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/0001640334-25-002225-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-08-31.

Profile

FieldValue
TickerLEXX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001348362

Financials · 2025

LineValue
Revenue$706K
Net income-$11.9M
Operating income-$11.9M
Net margin-1686.0%
Operating margin-1683.0%
Revenue growth+52.0%
Cash$1.8M
Total assets$4.2M
P/E (computed)Net income was not positive
P/S (computed)13.2×

Warning signs

Cash runway
5.7 months
$3.5M cash at May 31, 2026
Share count, 1 year
+26.7%
2025-07-11 to 2026-07-13 · +206.3% over 3 years
Going-concern doubt
Yes
10-Q filed July 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, there is substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these financial statements."
10-Q 2026-07-13
Cash and burn$3.5M cash; operating cash flow -$1.9M a quarter.Report 2026-05-31
Shares outstanding1,652,496 (2026-07-13); 19,559,179 a year earlier; 8,091,650 three years earlier.Cover page 2026-07-13
Reverse splits, 3 years1; latest 1-for-15 on 2026-08-03Source 2026-08-03
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-16
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-10
Delisting25-NSE filed25-NSE 2026-01-14
AuditorMaloneBailey, LLP, Houston, Texas, United StatesPCAOB Form AP 2025-12-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-05-31
$0-$2.0M-$1.6M$3.5MNo debt tags$194K10-Q 2026-07-13
Q2 2026
2026-02-28
$20K-$1.4M-$2.2M$5.1MNo debt tags$368K10-Q 2026-04-13
Q1 2026
2025-11-30
$0-$1.6M-$984K$4.3MNo debt tags$522K10-Q 2026-01-13
Q4 2025
2025-08-31
$174K-$2.7M-$2.6M$1.8MNo debt tags$706K10-K 2025-11-28
Q3 2025
2025-05-31
$174K-$3.8M-$3.6M$4.6MNo debt tags$616K10-Q 2026-07-13
Q2 2025
2025-02-28
$174K-$2.7M-$1.5M$6.5MNo debt tags$526K10-Q 2026-04-13
Q1 2025
2024-11-30
$184K-$2.7M-$2.7M$8.1MNo debt tags$497K10-Q 2026-01-13
Q4 2024
2024-08-31
$84K-$2.2M-$1.9M$6.5MNo debt tags$464K10-K 2025-11-28

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-1.3%
1 month+58.6%
3 months-45.2%
Year to date-52.0%
1 year-73.1%
From 52-week high-77.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GDTCCytoMed Therapeutics Limited$0.7739-6.68%$9.2M
BFRGBullfrog AI Holdings Inc.$0.4878-9.92%$9.0M
PHIOPhio Pharmaceuticals Corp.$0.7522-2.44%$9.0M
AEONAEON Biopharma Inc.$0.1407-8.04%$10.1M
VTGNVistagen Therapeutics Inc.$0.1843+2.11%$8.5M
CLRBCellectar Biosciences Inc.$1.01-11.40%$10.1M
BFRIBiofrontera Inc.$0.5700-18.58%$10.2M
CALCCalciMedica Inc.$1.19-1.65%$8.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier